These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 16413505)

  • 1. Epidermal growth factor receptor inhibitor (PD168393) potentiates cytotoxic effects of paclitaxel against androgen-independent prostate cancer cells.
    Pu YS; Hsieh MW; Wang CW; Liu GY; Huang CY; Lin CC; Guan JY; Lin SR; Hour TC
    Biochem Pharmacol; 2006 Mar; 71(6):751-60. PubMed ID: 16413505
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeted inhibition of the epidermal growth factor receptor-tyrosine kinase by ZD1839 ('Iressa') induces cell-cycle arrest and inhibits proliferation in prostate cancer cells.
    Sgambato A; Camerini A; Faraglia B; Ardito R; Bianchino G; Spada D; Boninsegna A; Valentini V; Cittadini A
    J Cell Physiol; 2004 Oct; 201(1):97-105. PubMed ID: 15281092
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of cytotoxic agents against human tumor xenografts is markedly enhanced by coadministration of ZD1839 (Iressa), an inhibitor of EGFR tyrosine kinase.
    Sirotnak FM; Zakowski MF; Miller VA; Scher HI; Kris MG
    Clin Cancer Res; 2000 Dec; 6(12):4885-92. PubMed ID: 11156248
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Studies with CWR22 xenografts in nude mice suggest that ZD1839 may have a role in the treatment of both androgen-dependent and androgen-independent human prostate cancer.
    Sirotnak FM; She Y; Lee F; Chen J; Scher HI
    Clin Cancer Res; 2002 Dec; 8(12):3870-6. PubMed ID: 12473602
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synergistic antiproliferative and apoptotic effects induced by mixed epidermal growth factor receptor inhibitor ZD1839 and nitric oxide donor in human prostatic cancer cell lines.
    Mimeault M; Jouy N; Depreux P; Hénichart JP
    Prostate; 2005 Feb; 62(2):187-99. PubMed ID: 15389789
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Epidermal growth factor receptor (HER1) tyrosine kinase inhibitor ZD1839 (Iressa) inhibits HER2/neu (erbB2)-overexpressing breast cancer cells in vitro and in vivo.
    Moulder SL; Yakes FM; Muthuswamy SK; Bianco R; Simpson JF; Arteaga CL
    Cancer Res; 2001 Dec; 61(24):8887-95. PubMed ID: 11751413
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel combination therapy against metastatic and androgen-independent prostate cancer by using gefitinib, tamoxifen and etoposide.
    Mimeault M; Venkatraman G; Johansson SL; Moore E; Henichart JP; Depreux P; Lin MF; Batra SK
    Int J Cancer; 2007 Jan; 120(1):160-9. PubMed ID: 17013895
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Improvement of cytotoxic effects induced by mitoxantrone on hormone-refractory metastatic prostate cancer cells by co-targeting epidermal growth factor receptor and hedgehog signaling cascades.
    Mimeault M; Mehta PP; Hauke R; Henichart JP; Depreux P; Lin MF; Batra SK
    Growth Factors; 2007 Dec; 25(6):400-16. PubMed ID: 18365871
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of growth factor production and angiogenesis in human cancer cells by ZD1839 (Iressa), a selective epidermal growth factor receptor tyrosine kinase inhibitor.
    Ciardiello F; Caputo R; Bianco R; Damiano V; Fontanini G; Cuccato S; De Placido S; Bianco AR; Tortora G
    Clin Cancer Res; 2001 May; 7(5):1459-65. PubMed ID: 11350918
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor.
    Ciardiello F; Caputo R; Bianco R; Damiano V; Pomatico G; De Placido S; Bianco AR; Tortora G
    Clin Cancer Res; 2000 May; 6(5):2053-63. PubMed ID: 10815932
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of angiogenesis by the antiepidermal growth factor receptor antibody ImClone C225 in androgen-independent prostate cancer growing orthotopically in nude mice.
    Karashima T; Sweeney P; Slaton JW; Kim SJ; Kedar D; Izawa JI; Fan Z; Pettaway C; Hicklin DJ; Shuin T; Dinney CP
    Clin Cancer Res; 2002 May; 8(5):1253-64. PubMed ID: 12006546
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cytotoxic effects induced by a combination of cyclopamine and gefitinib, the selective hedgehog and epidermal growth factor receptor signaling inhibitors, in prostate cancer cells.
    Mimeault M; Moore E; Moniaux N; Hénichart JP; Depreux P; Lin MF; Batra SK
    Int J Cancer; 2006 Feb; 118(4):1022-31. PubMed ID: 16108016
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Enediyne lidamycin enhances the effect of epidermal growth factor receptor tyrosine kinase inhibitor, gefitinib, in epidermoid carcinoma A431 cells and lung carcinoma H460 cells.
    Liu H; Li L; Li XQ; Liu XJ; Zhen YS
    Anticancer Drugs; 2009 Jan; 20(1):41-9. PubMed ID: 19342999
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Methylseleninic acid potentiates apoptosis induced by chemotherapeutic drugs in androgen-independent prostate cancer cells.
    Hu H; Jiang C; Ip C; Rustum YM; Lü J
    Clin Cancer Res; 2005 Mar; 11(6):2379-88. PubMed ID: 15788689
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Response to epidermal growth factor receptor inhibitors in non-small cell lung cancer cells: limited antiproliferative effects and absence of apoptosis associated with persistent activity of extracellular signal-regulated kinase or Akt kinase pathways.
    Janmaat ML; Kruyt FA; Rodriguez JA; Giaccone G
    Clin Cancer Res; 2003 Jun; 9(6):2316-26. PubMed ID: 12796401
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combination of a selective cyclooxygenase-2 inhibitor with epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 and protein kinase A antisense causes cooperative antitumor and antiangiogenic effect.
    Tortora G; Caputo R; Damiano V; Melisi D; Bianco R; Fontanini G; Veneziani BM; De Placido S; Bianco AR; Ciardiello F
    Clin Cancer Res; 2003 Apr; 9(4):1566-72. PubMed ID: 12684433
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antisense TRPM-2 oligodeoxynucleotides chemosensitize human androgen-independent PC-3 prostate cancer cells both in vitro and in vivo.
    Miyake H; Chi KN; Gleave ME
    Clin Cancer Res; 2000 May; 6(5):1655-63. PubMed ID: 10815883
    [TBL] [Abstract][Full Text] [Related]  

  • 18. ZD1839 (Gefitinib, 'Iressa'), an epidermal growth factor receptor-tyrosine kinase inhibitor, enhances the anti-cancer effects of TRAIL in human esophageal squamous cell carcinoma.
    Teraishi F; Kagawa S; Watanabe T; Tango Y; Kawashima T; Umeoka T; Nisizaki M; Tanaka N; Fujiwara T
    FEBS Lett; 2005 Aug; 579(19):4069-75. PubMed ID: 16023108
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antitumor activity of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor gefitinib (ZD1839, Iressa) in non-small cell lung cancer cell lines correlates with gene copy number and EGFR mutations but not EGFR protein levels.
    Helfrich BA; Raben D; Varella-Garcia M; Gustafson D; Chan DC; Bemis L; Coldren C; Barón A; Zeng C; Franklin WA; Hirsch FR; Gazdar A; Minna J; Bunn PA
    Clin Cancer Res; 2006 Dec; 12(23):7117-25. PubMed ID: 17145836
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Signaling mechanisms that mediate invasion in prostate cancer cells.
    Bonaccorsi L; Marchiani S; Muratori M; Carloni V; Forti G; Baldi E
    Ann N Y Acad Sci; 2004 Dec; 1028():283-8. PubMed ID: 15650253
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.